|DB13539||Iodoxamic acid||Not Available|
|DB00225||Gadodiamide||For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.|
|DB00271||Diatrizoate||Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium.|
|DB00538||Gadoversetamide||Gadoversetamide is an MRI contrast agent used for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors.|
|DB00556||Perflutren||Used as an ultrasound contrast imaging in cardiology and radiology.|
|DB00597||Gadoteridol||Gadoteridol is an MRI contrast agent used for contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.|
|DB00693||Fluorescein||For diagnostic imaging. Primarily indicated in diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature.|
|DB00743||Gadobenic acid||Gadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for MRI of the heart, as well as and central nervous system in adults to visualize lesions with abnormal brain vascularity or abnormalities in the blood brain barrier, the brain, spine, or other associated tissues.|
|DB00789||Gadopentetate dimeglumine||For use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues as well as lesions with abnormal vascularity in the head and neck. Also used to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart).|
|DB00965||Ethiodized oil||For use as a radio-opaque medium for hysterosalpingography and lymphography, and as an antineoplastic agent when part of the iodine is 131-I. It is also used in follow-up imaging for chemoembolization.|
|DB01187||Iophendylate||Iophendylate is used as a contrast agent to locate spinal tumors.|
|DB01249||Iodixanol||Iodixanol is a contrast agent during coronary angiography.|
|DB01362||Iohexol||Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.|
|DB01578||Metrizamide||Metrizamide is used for lumbar, thoracic, cervical, and total columnar myelography to determine the presence of abnormalities in the spinal column, spinal canal, and central nervous system (CNS) as well as for cisternography by direct injection using standard radiologic techniques to visualize the basal cistern of the brain. For computerized tomography (CT) of the intracranial subarachnoid spaces and for ventriculography by direct injection using standard radiologic techniques to visualize the cerebral ventricles. Also used in pediatric angiocardiography to visualize lesions or malformations of the heart and obstructions or anomalies of the major thoracic vessels. Also used in adult peripheral arteriography to visualize specific regions of the vascular system and blood flow in such areas to help in the diagnosis and evaluation of neoplasms (known or suspected) or vascular diseases (congenital or acquired) that may cause changes in normal vascular anatomy or physiology. Metrizamide is also indicated in adults for intravenous digital arteriography of head and neck.|
|DB04711||Iodipamide||Iodipamide is used as a contrast agent for cholecystography and intravenous cholangiography.|
|DB05428||motexafin gadolinium||Investigated for use/treatment in brain cancer, cancer/tumors (unspecified), lung cancer, and lymphoma (non-hodgkin's).|
|DB05528||Mipomersen||Used in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications.|
|DB05791||Perflubron||Investigated for use/treatment in cardiac surgery, hemorrhage, and ileus.|
|DB06642||Bevasiranib||Investigated for use/treatment in macular degeneration and diabetic retinopathy.|
|DB06703||Gadobutrol||For diagnostic use only. Indicated for adults and children age 2 and over for contrast enhancement during cranial and spinal MRI, and for contrast-enhanced magnetic resonance angiography (CE-MRA). Gadobutrol is particularly suited for the detection of very small lesions and for the visualization of tumors that do not readily take up contrast media. It may be a desired agent when the exclusion or demonstration of an additional pathology may influence the choice of therapy or patient management. It may also be suitable for perfusion studies in the diagnosis of stroke, detection of focal cerebral ischemia, and in studies of tumor perfusion. |
|DB06704||Iobenguane||Detection of primary and metastatic pheochromocytoma or neuroblastoma |
|DB06705||Gadofosveset trisodium||Gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.|
|DB06759||Fomivirsen||Indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS), when other therapy has been ineffective or is considered unsuitable [FDA Label, L1428].|
|DB06796||Mangafodipir||Indicated for use as an organ-specific paramagnetic contrast agent developed for imaging of the hepatobiliary system and detecting lesions in liver and pancreas.|
|DB08884||Gadoxetic acid||Gadoxetate is used as a contrast medium for magnetic resonance imaging (MRI) to detect and characterize lesions in the liver. |
|DB08945||Iotroxic acid||Not Available|
|DB08946||Iopanoic acid||Not Available|
|DB09132||Gadoteric acid||Gadoteric acid is indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.|
|DB09133||Iothalamic acid||Conray is indicated for use in excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast enhancement of computed tomographic brain images, cranial computerized angiotomography, intravenous digital subtraction angiography and arterial digital subtraction angiography.
Conray may also be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space.|
|DB09134||Ioversol||Optiray 350 is indicated in adults for peripheral and coronary arteriography and left ventriculography. Optiray 350 is also indicated for contrast enhanced computed tomographic imaging of the head and body, intravenous excretory urography, intravenous digital subtraction angiography and venography. Optiray 350 is indicated in children for angiocardiography.
Optiray 320 is indicated in adults for angiography throughout the cardiovascular system. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography. Optiray 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.
Optiray 320 is indicated in children for angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.
Optiray 300 is indicated for cerebral angiography and peripheral arteriography. Optiray 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography.
Optiray 240 is indicated for cerebral angiography and venography. Optiray 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography.|
|DB09135||Ioxilan||When administered intra-arterially, Ioxilan is indicated for the following diagnostic tests: cerebral arteriography (300 mgI/mL), coronary arteriography and left ventriculography (350 mgI/mL), visceral angiography(350 mgI/mL), aortography(350 mgI/mL), and peripheral arteriography(350 mgI/mL).
When administered intravenously, Ioxilan is indicated for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body (300 and 350 mgI/mL).|
|DB09137||Technetium Tc-99m mebrofenin||Technetium Tc 99m Mebrofenin is indicated as a hepatobiliary imaging agent.|
|DB09138||Technetium Tc-99m medronate||Technetium Tc 99m Medronate is indicated for use as a bone imaging agent to delineate areas of altered osteogenesis.|
|DB09156||Iopromide||Iopromide, as the product Iovist, is indicated for use as an X-ray contrast agent in the following procedures:
Intra-arterial digital subtraction angiography (IA-DSA) (150 mg I/mL)
Cerebral arteriography and peripheral arteriography (300 mg I/mL)
Coronary arteriography and left ventriculography, visceral angiography and aortography (370 mg I/mL)
Peripheral venography (240 mg I/mL)
Excretory urography (300 mg I/mL)
Contrast computed tomography (CT) imaging of head and body (300 mg I/mL and 370 mg I/mL) |
|DB09161||Technetium Tc-99m sestamibi||Technetium Tc 99m Sestamibi is indicated for: 1) detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects); and 2) evaluating myocardial function and developing information for use in patient management decisions.|
|DB09163||Technetium Tc-99m exametazime||Technetium Tc99m exametazime scintigraphy (with or without methylene blue stabilization) may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime without methylene blue stabilization is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.|
|DB09164||Technetium Tc-99m disofenin||Technetium Tc99m Disofenin is indicated as a hepatobiliary imaging agent. Hepatolite is indicated in the diagnosis of acute cholecystitis as well as to rule out the occurrence of acute cholecystitis in suspected patients with right upper quadrant pain, fever, jaundice, right upper quadrant tenderness and mass or rebound tenderness, but not limited to these signs and symptoms.|
|DB09165||Technetium Tc-99m pyrophosphate||For use as a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction [FDA Label]. May also be used to image gated blood pools and detect gastrointetinal bleeding.|
|DB09313||Ioxaglic acid||This medicinal product is for diagnostic use only in adults and children as a low-osmolality medium [L1883], [A7924]. |
|DB09314||Technetium Tc-99m pertechnetate||Sodium Pertechnetate Tc99m Injection is indicated for use in adults for imaging in the following tissues: thyroid, salivary gland, urinary bladder (for detection of vesico-ureteral reflux), and nasolacrimal drainage system (dacryoscintigraphy). It is indicated for use in children for imaging the following tissues: thyroid and urinary bladder.
|DB09333||Iopodic acid||Iopodic acid is available as a cholecystographic agent. This denomination indicates the iopodic acid is a radiopaque substance that can be used to visualize the gallbladder and biliary channels in abdominal X-ray.[L1587, A32087] An abdominal X-ray uses a minimal amount of ionizing radiation to produce pictures of the inside of the abdominal cavity. It is commonly used to evaluate the stomach, liver, intestines, and spleen.[L1589]
Iopodic acid has also been indicated for the treatment of hyperthyroidism such as Graves disease.[A32085, A32086] Hyperthyroidism refers to any condition where there is too much thyroid hormone produced in the body (overactive thyroid). When the overactivity involves the entire thyroid gland, it is known as Grave's disease.[L1590]|
|DB09340||Tyropanoic acid||For use in cholecystography (X-ray diagnosis/imaging of gallstones).|
|DB09346||Metrizoic acid||For use as a contrast medium [L1597].|
|DB09347||Acetrizoic acid||Acetrizoic acid indication was to be used as a contrast agent for X-ray. Some information indicates its nephrotropic property as one of the characteristics for the utilization of acetrizoic acid.[A32135] The X-ray imaging depends on the difference in tissue density which is provided by an X-ray attenuation between the area of interest and the surrounding tissue. The use of contrast agents will provoke a contrast enhancement or opacification and it will improve the differentiation of pathological processes from normal tissue.[T125]|
|DB09397||Technetium Tc-99m sulfur colloid||Technetium 99m sulfur colloid is indicated as a diagnostic agent in adults for the following tests: localization of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma; and evaluation of peritoneo-venous (LeVeen) shunt patency. It is indicated in both adult and pediatric patients for: imaging areas of functioning reticuloendothelial cells in the liver, spleen and bone marrow; and studies of esophageal transit and gastroesophageal reflux, and detection of pulmonary aspiration of gastric contents.|
|DB09502||Fludeoxyglucose F-18||The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which in turn is closely correlated with certain types of tissue metabolism.
Fludeoxyglucose F 18 Injection is indicated in positron emission tomography (PET) imaging for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnoses of cancer. |
|DB11150||Barium sulfate|| Barium sulfate is a radiographic contrast agent indicated for use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in adult and pediatric patients [FDA label].|